{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "10442275",
  "DateCompleted": {
    "Year": "1999",
    "Month": "10",
    "Day": "14"
  },
  "DateRevised": {
    "Year": "2004",
    "Month": "11",
    "Day": "17"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0378-6501",
      "JournalIssue": {
        "Volume": "25",
        "Issue": "4",
        "PubDate": {
          "Year": "1999"
        }
      },
      "Title": "Drugs under experimental and clinical research",
      "ISOAbbreviation": "Drugs Exp Clin Res"
    },
    "ArticleTitle": "Is inhaled corticosteroid useful as adjunctive management in tuberculous pyrexia?",
    "Pagination": {
      "StartPage": "179",
      "EndPage": "184",
      "MedlinePgn": "179-84"
    },
    "Abstract": {
      "AbstractText": [
        "Systemic corticosteroid is currently the standard adjunctive therapy for tuberculous pyrexia. A preliminary prospective open study to examine the efficacy of inhaled budesonide at a dose of 2,400 micrograms daily in the management of this condition was performed. Out of nine non-HIV infected patients with tuberculous pyrexia studied, four patients succeeded to achieve defervescence at a mean of 3.25 days (range = 2 to 5 days), while the rest of the patients failed to do so within 7 days. None of the patients had unwanted side effects of systemic corticosteroid and patients' acceptance of such therapy was high. The potential usefulness of inhaled corticosteroid in some patients with tuberculous pyrexia might warrant further evaluation."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong, China."
          }
        ],
        "LastName": "Yew",
        "ForeName": "W W",
        "Initials": "WW"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Chau",
        "ForeName": "C H",
        "Initials": "CH"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Lee",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Leung",
        "ForeName": "C K",
        "Initials": "CK"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Controlled Clinical Trial",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Drugs Exp Clin Res",
    "NlmUniqueID": "7802135",
    "ISSNLinking": "0378-6501"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "51333-22-3",
      "NameOfSubstance": "Budesonide"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Administration, Inhalation"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Budesonide"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Chemotherapy, Adjuvant"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Tuberculosis, Pulmonary"
    }
  ]
}